BC Technical and UltraSPECT Inc. have entered into a long-term agreement to provide their customers easier access to UltraSPECT products across the nation.
Mobius Medical Systems LP’s Mobius3D software has received U.S. market clearance as a Class II medical device from the U.S. Food and Drug Administration (FDA).
Governor Deval Patrick has signed Massachusetts’ breast density inform bill into law (Chapter 150) this week, making Massachusetts the 18th state to enact a such legislation.
If you enjoy this content, please share it with a colleague
Call-backs have always been a problem in mammography. They are a source of worry, added discomfort, well-founded patient complaints about the inefficiency of breast exams, and unnecessary cost. More than that, they call into question the credibility of an exam whose use depends on women’s belief in its value.
Data from a new study of more than 170,000 examinations using 3-D mammography (breast tomosynthesis) screening technology finds 3-D significantly more invasive cancers than a traditional 2-D mammogram. The researchers also found that 3-D mammography reduces the number of women called back for unnecessary testing due to false alarms. The study was published in the June 25, 2014 issue of the Journal of the American Medical Association (JAMA).
If you enjoy this content, please share it with a colleague
Thanks to its excellent dielectric properties and a reliable surface finish, a high-quality alumina ceramic from Morgan Advanced Materials is now being successfully used in radiotherapy equipment for oncology treatment.
NYU Langone Medical Center is now using a novel technology that serves as a "flight simulator" for neurosurgeons, allowing them to rehearse complicated brain surgeries before making an actual incision on a patient.
Shimadzu Medical Systems USA has announced that its Dallas-headquartered direct sales and service division has expanded its territory to include the western half of the state of Arkansas.
Researchers have announced the results of a study that used speckle-tracking echocardiography (STE) to analyze early phase one results from the multi-center COMPASSION trial, which seeks to examine the safety and efficacy of a new option to replace dysfunctional pulmonary valves in a subset of congenital heart disease patients.
